Glecirasib

DRUG3 trials

Sponsors

Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

KRAS G12CLung Cancer Stage IIIMutationNSCLC Stage IVNon-small Cell Lung Cancer

Phase 1

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Not yet recruitingNCT07339839

Cancer Institute and Hospital, Chinese Academy of Medical SciencesKRAS G12C, NSCLC Stage IV

Start: 2026-03-01End: 2029-09-30Target: 42Updated: 2026-01-14

Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

RecruitingNCT06563999

Sun Yat-sen UniversityLung Cancer Stage III, Mutation

Start: 2024-11-01End: 2029-11-01Target: 120Updated: 2026-04-21

A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruitingNCT07827261

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2026-09-01End: 2028-12-01Target: 36Updated: 2026-09-18